GOMEKLI FDA Approved for Treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN), Available at Biologics by McKesson
CARY, N.C., FEBRUARY 18, 2025—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been […]
Romvimza (vimseltinib), FDA Approved for Treatment of Tenosynovial Giant Cell Tumor (TGCT), Available at Biologics by McKesson
CARY, N.C., February 17, 2025—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been […]
Danziten (nilotinib), FDA Approved for Treatment of Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia, Available at Biologics by McKesson
CARY, N.C., December 6, 2024—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been […]
ZOKINVY (lonafarnib), the only FDA Approved Treatment for Hutchinson-Gilford Progeria Syndrome, Now Exclusively Available at Biologics by McKesson
CARY, N.C., September 10, 2024 –Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease, was selected […]
RYTELO (imetelstat), FDA Approved for Treatment of Patients with Low- to Intermediate-1 Risk Myelodysplastic Syndromes (MDS) with Transfusion-dependent Anemia, Available at Biologics by McKesson
CARY, N.C., September 9, 2024—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected […]